Proteomics in prostate cancer biomarker discovery

Larkin, Samantha; Zeidan, Bashar; Taylor, M.; Bickers, Bridget; Alruwaili, Jamal; Aukim-Hastie, Claire; Townsend, Paul A.

doi:10.1586/epr.09.89

Cited by 19 publications

(16 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the improvements in clinical and surgical practice, prostate cancer (PCa) remains one of the most widespread cancers in males, with an unchanged mortality rate [1-4]. …”

Section: Introductionmentioning

confidence: 99%

Inflammation: an important parameter in the search of prostate cancer biomarkers

et al. 2014

View full text Add to dashboard Cite

BackgroundA more specific and early diagnostics for prostate cancer (PCa) is highly desirable. In this study, being inflammation the focus of our effort, serum protein profiles were analyzed in order to investigate if this parameter could interfere with the search of discriminating proteins between PCa and benign prostatic hyperplasia (BPH).MethodsPatients with clinical suspect of PCa and candidates for trans-rectal ultrasound guided prostate biopsy (TRUS) were enrolled. Histological specimens were examined in order to grade and classify the tumor, identify BPH and detect inflammation. Surface Enhanced Laser Desorption/Ionization-Time of Flight-Mass Spectrometry (SELDI-ToF-MS) and two-dimensional gel electrophoresis (2-DE) coupled with Liquid Chromatography-MS/MS (LC-MS/MS) were used to analyze immuno-depleted serum samples from patients with PCa and BPH.ResultsThe comparison between PCa (with and without inflammation) and BPH (with and without inflammation) serum samples by SELDI-ToF-MS analysis did not show differences in protein expression, while changes were only observed when the concomitant presence of inflammation was taken into consideration. In fact, when samples with histological sign of inflammation were excluded, 20 significantly different protein peaks were detected. Subsequent comparisons (PCa with inflammation vs PCa without inflammation, and BPH with inflammation vs BPH without inflammation) showed that 16 proteins appeared to be modified in the presence of inflammation, while 4 protein peaks were not modified. With 2-DE analysis, comparing PCa without inflammation vs PCa with inflammation, and BPH without inflammation vs the same condition in the presence of inflammation, were identified 29 and 25 differentially expressed protein spots, respectively. Excluding samples with inflammation the comparison between PCa vs BPH showed 9 unique PCa proteins, 4 of which overlapped with those previously identified in the presence of inflammation, while other 2 were new proteins, not identified in our previous comparisons.ConclusionsThe present study indicates that inflammation might be a confounding parameter during the proteomic research of candidate biomarkers of PCa. These results indicate that some possible biomarker-candidate proteins are strongly influenced by the presence of inflammation, hence only a well-selected protein pattern should be considered for potential marker of PCa.

show abstract

“…Despite the improvements in clinical and surgical practice, prostate cancer (PCa) remains one of the most widespread cancers in males, with an unchanged mortality rate [1-4]. …”

Section: Introductionmentioning

confidence: 99%

Inflammation: an important parameter in the search of prostate cancer biomarkers

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Notably, the most common proteomics methodologies are MS-based proteomics and protein microarray technology based proteomics. Using these methodologies, a gamut of proteomics biomarkers of PCa have already been identified [43–49], and some were demonstrated to potentially predict progression and aggressiveness of PCa [50–52]. However, successful application of omics based approaches is heavily dependent on available bioinformatics and computational biology resources, which remain limited in Africa.…”

Section: Prospects For Proteomics In Pca Biomarker Researchmentioning

confidence: 99%

Emerging proteomics biomarkers and prostate cancer burden in Africa

et al. 2017

View full text Add to dashboard Cite

Various biomarkers have emerged via high throughput omics-based approaches for use in diagnosis, treatment, and monitoring of prostate cancer. Many of these have yet to be demonstrated as having value in routine clinical practice. Moreover, there is a dearth of information on validation of these emerging prostate biomarkers within African cohorts, despite the huge burden and aggressiveness of prostate cancer in men of African descent. This review focusses of the global landmark achievements in prostate cancer proteomics biomarker discovery and the potential for clinical implementation of these biomarkers in Africa. Biomarker validation processes at the preclinical, translational and clinical research level are discussed here, as are the challenges and prospects for the evaluation and use of novel proteomic prostate cancer biomarkers.

show abstract

“…Proteomic analysis of PCa tissues associated with multistage tumor progression also provides a valuable source of clinically relevant biomarkers and novel therapeutic targets 130,131. For example, Ummanni et al132 recently reported the differential protein expression patterns from histologically characterized PCa tumor tissues and surrounding benign tissues of individual PCa patients based upon 2D differential gel electrophoresis coupled with MS.…”

Section: Target Discovery Based Upon Differential Disease State Tissumentioning

confidence: 99%

Advances in the proteomic discovery of novel therapeutic targets in cancer

Guo¹,

Zhang²,

Wang³

2013

DDDT

View full text Add to dashboard Cite

Proteomic approaches are continuing to make headways in cancer research by helping to elucidate complex signaling networks that underlie tumorigenesis and disease progression. This review describes recent advances made in the proteomic discovery of drug targets for therapeutic development. A variety of technical and methodological advances are overviewed with a critical assessment of challenges and potentials. A number of potential drug targets, such as baculoviral inhibitor of apoptosis protein repeat-containing protein 6, macrophage inhibitory cytokine 1, phosphoglycerate mutase 1, prohibitin 1, fascin, and pyruvate kinase isozyme 2 were identified in the proteomic analysis of drug-resistant cancer cells, drug action, and differential disease state tissues. Future directions for proteomics-based target identification and validation to be more translation efficient are also discussed.

show abstract

Proteomics in prostate cancer biomarker discovery

Cited by 19 publications

References 67 publications

Inflammation: an important parameter in the search of prostate cancer biomarkers

Inflammation: an important parameter in the search of prostate cancer biomarkers

Emerging proteomics biomarkers and prostate cancer burden in Africa

Advances in the proteomic discovery of novel therapeutic targets in cancer

Contact Info

Product

Resources

About